Navigation Links
New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia

AstraZeneca is a major international healthcare business engaged in the research, development, manufacture and marketing of prescription pharmaceuticals and the supply of healthcare services. It is one of the world's leading pharmaceutical companies with healthcare sales of $26.47 billion and leading positions in sales of gastrointestinal, cardiovascular, neuroscience, respiratory, oncology and infection products. AstraZeneca is listed in the Dow Jones Sustainability Index (Global) as well as the FTSE4Good Index.

In the United States, AstraZeneca is a $12.44 billion healthcare business with more than 12,000 employees. For nearly three decades, AstraZeneca has offered drug assistance programs side by side with its medicines, and over the past five years, has provided over $3 billion in savings to more than 1 million patients throughout the US and Puerto Rico. AstraZeneca has been named one of the "100 Best Companies for Working Mothers" by Working Mother magazine and is the only large pharmaceutical company named to FORTUNE magazine's 2007 list of "100 Best Companies to Work For." In 2006, for the fifth consecutive year, Science magazine named AstraZeneca a "Top Employer" on its ranking of the world's most respected biopharmaceutical employers.

For more information about AstraZeneca, please visit: http://www.astrazeneca-us.com .

The statements herein include forward-looking statements. By their nature, forward-looking statements and forecasts involve risk and uncertainty. For a discussion of those risks and uncertainties please see the company's Annual Report/Form 20-F for 2006.

    References:

    (1) C Schulz, R Kahn, V Palazov, E Reyes, D Meulien, M Brecher, O

        Svensson, HM Andersson. "Efficacy of Once-Daily Extended Release

        Quetiapine Fumarate in Patients with Acute Schizophrenia." Annual

        Meeting of the American Psychiatric Association, 2007
'"/>




Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:9/1/2014)... LONDON , Sept. 1, 2014 ... Brazil Aesthetic Lasers and Energy ... https://www.reportbuyer.com/product/2343455/Brazil-Aesthetic-Lasers-and-Energy-Devices-Market-Outlook-to-2020.html Brazil Aesthetic ... Summary GlobalData,s new ... Outlook to 2020", provides key market data on ...
(Date:9/1/2014)... Sept. 1, 2014 ... is available in its catalogue: Antibody ... http://www.reportlinker.com/p02280919/Antibody-Drug-Conjugates-Market-2nd-Edition-2014---2024.html ... new class of therapeutic agents, gaining increasing attention ... addressed as the marriage of an antibody with ...
(Date:9/1/2014)... YORK , Sept. 1, 2014 ... is available in its catalogue:  Drug Discovery ... http://www.reportlinker.com/p02349116/Drug-Discovery-Technologies---A-Global-Market-Overview.html The ... such as cancer requires extensive expenditure, in addition ... step in designing a new drug involves the ...
Breaking Medicine Technology:Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 2Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 3Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 4Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 5Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 6Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 7Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 8Brazil Aesthetic Lasers and Energy Devices Market Outlook to 2020 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 2Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 3Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 4Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 5Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 6Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 7Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 8Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 9Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 10Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 11Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 12Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 13Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 14Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 15Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 16Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 17Antibody Drug Conjugates Market (2nd Edition), 2014 - 2024 18Drug Discovery Technologies - A Global Market Overview 2Drug Discovery Technologies - A Global Market Overview 3Drug Discovery Technologies - A Global Market Overview 4Drug Discovery Technologies - A Global Market Overview 5Drug Discovery Technologies - A Global Market Overview 6Drug Discovery Technologies - A Global Market Overview 7Drug Discovery Technologies - A Global Market Overview 8Drug Discovery Technologies - A Global Market Overview 9Drug Discovery Technologies - A Global Market Overview 10Drug Discovery Technologies - A Global Market Overview 11
... 10, 2010 /PRNewswire-FirstCall/ -- HealthWarehouse.com, Inc ... leading VIPPS accredited retail mail-order pharmacy, announced today that ... equity and convertible debt with independent investors. ... company,s online presence while upgrading its technology infrastructure to ...
... 10, 2010 Nycomed US Inc. announced today the ... Vice President and General Counsel, reporting to Steve Andrzejewski, ... legal advisor of the company and oversee all of ... he will also be responsible for the company,s compliance ...
Cached Medicine Technology:HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 2HealthWarehouse.com Places $3.3 Million in Preferred Stock and $1 Million in Convertible Debt 3Joseph J. LaRosa Joins Nycomed US Inc. 2
(Date:9/1/2014)... 2014 The B-cell non-Hodgkin’s Lymphoma (NHL) ... major markets (the US, France, Italy, Germany, Spain and ... billion by 2018. , The competitive landscape in the ... Spain and the UK is poised to undergo a ... the four largest B-cell NHL indications, which includes Diffuse ...
(Date:9/1/2014)... 1 September 2014: Daily fruit consumption cuts the risk ... to research presented at ESC Congress today by Dr ... seven year follow-up study of nearly 0.5 million people ... fruit people ate, the more their risk of CVD ... disease (IHD) and stroke, is the leading cause of ...
(Date:9/1/2014)... 01, 2014 As well as having ... is currently pursuing counselor certification in Louisiana. ... the CPI training program as well as the ... grown both personally and professionally. I am not ... competently able to do so. As a Non ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 BCC Research ... BLOOD-BRAIN BARRIER TECHNOLOGIES AND GLOBAL MARKETS , the ... million in 2013 and is expected to reach $38.7 ... to $471.5 million by 2019, which is equivalent to ... 2019. The receptor-mediated transport (RMT) segment is forecasted to ...
(Date:9/1/2014)... In honor of National Take Your Cat to the Vet Day, ... of Minnesota (AERC) is offering a few reasons why pet owners ... people don’t take their cat to the vet because “there’s nothing ... decide not to take their kid to dentist because he or ... pets. Just like people want their loved ones to be healthy, ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3Health News:Narconon Louisiana Announces New Certifications For Staff 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 2Health News:Animal Emergency & Referral Center of Minnesota Celebrates National Take Your Cat to the Vet Day 3
... A 29-year-old Indonesian man has died of bird flu, bringing ... to 80, the world's highest, an official said Friday. ... in hospital Tuesday in Pekanbaru, capital of Riau province on ... at the Indonesian health ministry. ,"He had a ...
... been transferred back to the LA prison where she is ... medical ward. ,Jail authorities said that the hotel ... Towers Correctional Facility for less than a week. ... jail sentence for violating terms of probation, was taken to ...
... getting some extra sleep before a big game could ... ,Researcher Cheri Mah and colleagues at Stanford University observed ... ,They were told to maintain their usual sleeping habits ... they were instructed to get as much extra sleep ...
... over the legislation aimed at preventing discrimination of the HIV ... ,Union Health Minister Anbumani Ramadoss said that the HIV/AIDS bill ... with the NGOs on the issue that could guarantee safe-working ... ,The bill also provides for access to treatment ...
... identified by Yale School of Medicine researcher Michael Kozal, ... quickly detects rare viral mutations. ,Kozal, associate ... the retrospective study that used samples from an earlier ... International HIV Drug Resistance Workshop in Barbados. ...
... thought a toilet could save her so much time and money. ... shack in Kibera, Africa's largest slum, she realized it could. ... installed the latrine that uses human waste to produce gas to ... dwellers. ,"At first I thought it was a very ...
Cached Medicine News:Health News:Bill on HIV/AIDS Delayed Further 2Health News:HIV Drug Resistance can Be Identified by Genome Sequencing 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 2Health News:Bio-latrine Cleans Up Kenyan Slum and the Environment 3
The Thermal pads were designed to simulate water immersion, the most effective method of transferring energy non-invasively....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
The torso blanket is designed to affix to the lower abdominal area and cover the upper half of the body....
Cocoon Disposable Patient Warming Blankets are specially designed to prevent hypothermia and maintain normothermia in your patients. The soft warm coloured material is strong and resists tearing and ...
Medicine Products: